MedTrace Logo

Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

NCT07637929 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-06-10

No results posted yet for this study

Summary

Establishing real-world data of Chinese patients with CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) treated with Puzolcabtagene Autoleucel Injection to evaluate its effectiveness.

Conditions

  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL)

Interventions

DRUG

Puzolcabtagene Autoleucel Injection

An autologous T-cell suspension expressing the CD19 chimeric antigen receptor（CD19 CAR-T)

Sponsors & Collaborators

  • Chongqing Precision Biotech Co., Ltd

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2032-12-31
Completion
2032-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07637929 on ClinicalTrials.gov